Abla A. Creasey

Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis

Edward Abraham, Konrad Reinhart, Steven M. Opal et al. · JAMA · 2003 · 957 citations

Medicine, Pharmacology, Pharmacotherapy +15

Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor

Alice M. Wang, Abla A. Creasey, Martha Ladner et al. · Science · 1985 · 631 citations

Life Sciences, Biochemistry, Molecular Biology +9

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

Abla A. Creasey, Alvin Chang, Larry P. Feigen et al. · Journal of Clinical Investigation · 1993 · 554 citations · Full text

Veterinary Medicine, Immunology, Pharmacology +15

Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia

Evert de Jonge, Pascale E. P. Dekkers, Abla A. Creasey et al. · Blood · 2000 · 256 citations

Medicine, Immunology, Pharmacology +12

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study

Edward Abraham, Konrad Reinhart, Petr Svoboda et al. · Critical Care Medicine · 2001 · 253 citations

Medicine, Pharmacology, Pharmacotherapy +16